Tags: J&J | actelion | Swiss | biotechnology

J&J Discussing Breaking up Actelion in Acquisition

Image: J&J Discussing Breaking up Actelion in Acquisition

Thursday, 29 Dec 2016 12:01 PM

Johnson & Johnson is negotiating a deal to acquire Swiss biotechnology company Actelion Ltd. that would separate its commercialized portfolio from its research and development (R&D) assets, people familiar with the matter said on Thursday.

This deal structure would allow J&J to acquire Actelion with a cash offer in the region of $260 per share, a little more than what it had offered when it walked away from negotiations earlier this month, while allowing Actelion shareholders to benefit further financially from Actelion's R&D pipeline, the people said.

Under the deal being discussed, Actelion's R&D pipeline would be placed in a new publicly traded company, the people said. The exact ownership of this new company, and whether Actelion Chief Executive Jean-Paul Clozel would head that new company, are among the details still being negotiated, the people said.

A deal could be finalized by late January, the people said, cautioning that negotiations could still end without a deal and asking not to be identified because the details are confidential.

J&J and Actelion declined to comment.

© 2017 Thomson/Reuters. All rights reserved.

 
1Like our page
2Share
Companies
Johnson & Johnson is negotiating a deal to acquire Swiss biotechnology company Actelion Ltd. that would separate its commercialized portfolio from its research and development (R&D) assets, people familiar with the matter said on Thursday.
J&J, actelion, Swiss, biotechnology
173
2016-01-29
Thursday, 29 Dec 2016 12:01 PM
Newsmax Inc.
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved